Head-To-Head Comparison: Invivo Therapeutics (NVIV) vs. Its Rivals

Invivo Therapeutics (NASDAQ: NVIV) is one of 78 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Invivo Therapeutics to related companies based on the strength of its risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

12.8% of Invivo Therapeutics shares are held by institutional investors. Comparatively, 51.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 3.9% of Invivo Therapeutics shares are held by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Invivo Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivo Therapeutics 0 1 0 0 2.00
Invivo Therapeutics Competitors 280 1881 3399 109 2.59

Invivo Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 622.89%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 0.57%. Given Invivo Therapeutics’ higher probable upside, equities analysts clearly believe Invivo Therapeutics is more favorable than its peers.

Profitability

This table compares Invivo Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivo Therapeutics N/A -134.23% -109.16%
Invivo Therapeutics Competitors -152.28% -23.63% -9.48%

Volatility and Risk

Invivo Therapeutics has a beta of 3.19, suggesting that its share price is 219% more volatile than the S&P 500. Comparatively, Invivo Therapeutics’ peers have a beta of 1.21, suggesting that their average share price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Invivo Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Invivo Therapeutics N/A -$23.43 million -0.98
Invivo Therapeutics Competitors $2.14 billion $234.27 million -86.86

Invivo Therapeutics’ peers have higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Invivo Therapeutics peers beat Invivo Therapeutics on 9 of the 13 factors compared.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit